XORTX Therapeutics (XRTX) Accounts Payables (2020 - 2026)
XORTX Therapeutics (XRTX) posted Accounts Payables of $844932.0 for Q1 2026, up 52.57% on a QoQ basis from $553784.0 in Q4 2025, and up 103.26% year-over-year from $415688.0 in Q1 2025.
XORTX Therapeutics (XRTX) Accounts Payables (2020 - 2026) Analysis & Trends
XORTX Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $844932.0 for Q1 2026.
- Quarterly Accounts Payables rose 103.26% year-over-year to $844932.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $844932.0 (up 103.26% YoY) and the FY2025 annual result came in at $553784.0, up 276.2% from the prior year.
- Accounts Payables was $844932.0 for Q1 2026 at XORTX Therapeutics, up from $553784.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $1.4 million in Q4 2022 and bottomed at $147205.0 in Q4 2024.
- A 5-year average of $596758.5 and a median of $525245.0 in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables sank 80.38% — and 2025, when it jumped 276.2%.
- XORTX Therapeutics' Accounts Payables stood at $1.4 million in 2022, then sank by 80.38% to $283428.0 in 2023, then sank by 48.06% to $147205.0 in 2024, then soared by 276.2% to $553784.0 in 2025, then jumped by 52.57% to $844932.0 in 2026.
- Business Quant data shows XRTX's Accounts Payables at $844932.0 in Q1 2026, $553784.0 in Q4 2025, and $677314.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - | 844,932.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 844,932.00 |
| Dec 31, 2025 | 553,784.00 |
| Sep 30, 2025 | 677,314.00 |
| Jun 30, 2025 | 453,982.00 |
| Mar 31, 2025 | 415,688.00 |
| Dec 31, 2024 | 147,205.00 |
| Sep 30, 2024 | 326,283.00 |
| Jun 30, 2024 | 437,938.00 |
| Mar 31, 2024 | 326,891.00 |
| Dec 31, 2023 | 283,428.00 |
| Sep 30, 2023 | 525,245.00 |
| Jun 30, 2023 | 358,077.00 |
| Mar 31, 2023 | 538,252.00 |
| Dec 31, 2022 | 1.44 Mn |
| Sep 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 712,797.81 |
| Mar 31, 2022 | 675,670.16 |
| Dec 31, 2021 | 556,127.80 |
| Sep 30, 2021 | 569,465.96 |
| Dec 31, 2020 | 793,297.91 |